This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Honjo, Y. Articles by Bates, S. E. Search for Related Content PubMed PubMed Citation Articles by Honjo, Y. Articles by Bates, S. E.

Acquired Mutations in the MXR/BCRP/ABCP Gene Alter Substrate Specificity in MXR/BCRP/ABCP-overexpressing Cells

Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 [Y. H., Q-W. Y., W. Y. M-P., R. W. R., A. v. d. L., S. E. B.]; Department of Chemistry, Purdue University, West Lafayette, Indiana 47907-1393 [C. A. H.]; Department of Medical Physiology, The Panum Institute, University of Copenhagen, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark [T. L.]; and Laboratory of Genomic Diversity, National Cancer Institute, Frederick, Maryland 21702 [M. D.]

	ABSTRACT

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

 
A disparity was noted in the transport of rhodamine 123 among nine MXR/BCRP/ABCP-overexpressing cells studied; all demonstrated mitoxantrone transport, whereas only two effluxed rhodamine 123. When the MXR/BCRP/ABCP gene was sequenced in the cell lines studied, differences were noted at amino acid 482, predicted to be at the start of the third transmembrane domain. Sequencing genomic DNA revealed wild-type MXR/BCRP/ABCP to have an arginine at position 482. Cells having a threonine or glycine at position 482 were able to efflux rhodamine 123, whereas cells having an arginine were not. A vaccinia virus expression system confirmed that rhodamine as well as doxorubicin efflux is observed with R482T or R482G but not with the wild-type R482; all three MXR/BCRP/ABCP forms transported mitoxantrone. Cross-resistance studies suggest that, compared with wild-type MXR/BCRP/ABCP, cells having an R482T mutation have higher anthracycline resistance, whereas an R482G mutation seems to confer relatively less resistance to SN-38 and topotecan. These results suggest that amino acid 482 has a crucial role in MXR/BCRP/ABCP function and that mutation of a single amino acid residue significantly changes substrate specificity, thus altering the drug resistance phenotype.

	Introduction

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

 
The mitoxantrone resistance protein, MXR/BCRP/ABCP, has been shown to confer high levels of resistance to mitoxantrone as well as resistance to anthracyclines; selected camptothecins including topotecan and SN-38; and flavopiridol (1, 2, 3, 4, 5) . MXR/BCRP/ABCP is a half-transporter that belongs in the ABCG subfamily containing the Drosophila white protein, which is involved in the transport of precursors of eye pigment (6) . The Human Genome Nomenclature Committee recently changed the gene symbol to ABCG2.² Recently, two new members of the ABCG subfamily (ABCG5 and ABCG8) have been identified that are involved in sterol transport (7 , 8) . Because MXR/BCRP/ABCP is a half-transporter, it is believed to dimerize in order to function (6) . MXR/BCRP/ABCP may be involved in the maternal-fetal xenobiotic barrier, because an inhibitor increased accumulation of topotecan in the fetus in mice lacking the multidrug transporter mdr1a/1b (9) . Studies in drug-resistant cells with overexpression of MXR/BCRP/ABCP show localization to the plasma membrane and efflux of substrates. In developing a flow cytometric assay for the detection of MXR/BCRP/ABCP, a disparity was noted in the transport of rhodamine 123 in MXR/BCRP/ABCP-overexpressing cells. Whereas all these cells were found to transport mitoxantrone, some cells readily effluxed rhodamine 123, whereas others did not (10) . Initially, we attributed this problem to low sensitivity of rhodamine; however, studies with mitoxantrone-resistant sublines of MCF-7 expressing MXR/BCRP/ABCP mRNA at high levels also demonstrated no apparent rhodamine efflux. In light of the fact that mutations in Pgp derived from drug selection have been shown to alter substrate specificity (11) , the MXR/BCRP/ABCP mRNA from 11 cell lines was sequenced to determine whether mutations could explain the differing substrate specificities. In the present study, we describe an acquired mutation in the MXR/BCRP/ABCP gene that correlates with the observed differences in rhodamine 123 transport and is associated with shifts in the cross-resistance profile of drug-resistant cells.

	Materials and Methods

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

 
Cell Lines.
Nine MXR/BCRP/ABCP-overexpressing sublines and two parental cell lines were examined in this study. MCF-7 AdVp3000 cells were maintained in 5 µg/ml verapamil and 3000 ng/ml adriamycin. Three sublines independently selected in mitoxantrone were also used: MCF-7/MX (12) , MCF-7 MX8, and MCF-7 MX100. These were maintained in 600 nM, 8 ng/ml, and 100 nM mitoxantrone, respectively. The MCF-7 FLV1000 cells were maintained in 1000 nM flavopiridol (5) . The human colon carcinoma cell line S1 and its drug-resistant subline S1-M1-3.2 were obtained from Dr. Lee M. Greenberger (Wyeth-Ayerst; Ref. 13 ). The S1-M1-80 subline was generated in our lab by exposing the S1-M1-3.2 cell line to increasing concentrations of mitoxantrone eventually reaching 80 µM (1) . The A549 MX10, NCI-H460 MX10, and SF295 MX10 cell lines were selected and maintained in 10 nM mitoxantrone (10) . The MCF-7 parental cells and resistant sublines were maintained in Improved Minimal Essential Medium, and the remaining cells and sublines were maintained in RPMI; both were supplemented with 10% FBS,³ 2 mM L-glutamine, 100 units/ml penicillin, and 100 µg/ml streptomycin. HeLa cells are grown in DMEM.

Immunoblot Analysis.
Cellular membrane proteins were prepared, and immunoblotting was performed as described previously using the polyclonal antibody 87405 (14) .

Mitoxantrone and Rhodamine Efflux Assays.
The efflux assays were based on those described previously (10 , 15) . Briefly, cells were suspended in complete medium alone (phenol red-free IMEM with 10% FCS), complete medium containing rhodamine 123 (0.5 µg/ml), or mitoxantrone (20 µM) with or without 10 µM FTC and incubated at 37°C in 5% CO₂ for 30 min. FTC has been shown previously to block MXR/BCRP/ABCP-mediated drug transport (13) . The cells were then washed with ice-cold complete media and either placed on ice or incubated for 1 h at 37°C in 5% CO₂ in complete media with or without 10 µM FTC. This 1-h incubation allows drug efflux to occur, after which time the remaining drug is quantitated by measuring fluorescence. Previous studies have shown that the histogram obtained after efflux in the presence or absence of FTC is a valid measurement of MXR/BCRP/ABCP function that correlates well with mRNA levels (10) . A FACSort flow cytometer with a 488-nm argon laser and 530-nm bandpass filter was used to read the fluorescence of rhodamine, whereas a FACSCalibur flow cytometer equipped with a 635-nm red diode laser and 670-nm bandpass filter was used to read the fluorescence of mitoxantrone. Vaccinia virus-infected cells were assayed similarly, except as noted in the legend to Fig. 2 .

View larger version (21K): [in this window] [in a new window] [Download PPT slide]   Fig. 2. Functional expression of MXR/BCRP/ABCP in transiently infected-transfected HeLa cells. HeLa cells were infected with vTF7-3 and transfected with pTM1-G482, pTM1-R482, or pTM1-T482 for 18 h. Mitoxantrone (20 µM) accumulation (A), rhodamine (0.5 µg/ml) accumulation (B), and doxorubicin (3 µM) accumulation (C) were determined in these cells after a 40-min incubation at 37°C in the presence of fluorescent substrate followed by a 20-min (mitoxantrone samples) or 40-min (rhodamine and doxorubicin samples) incubation in substrate-free media at 37°C. vTF7-3 infected cells transfected with pTM1 vector DNA were included as a negative control.

Vaccinia Virus Expression System.
Expression of MXR/BCRP/ABCP by an infection-transfection protocol was performed as described previously (15 , 16) . Cells were infected with recombinant vaccinia virus encoding bacteriophage T7 RNA polymerase (vTF7-3) and cotransfected with the expression plasmids pTM1-MXR/BCRP/ABCP (G482), pTM1-MXR/BCRP/ABCP (T482), and pTM1-MXR/BCRP/ABCP (R482) containing the human MXR/BCRP/ABCP gene variants at amino acid position 482. After 18–20 h, cells were harvested by trypsinization, washed in Opti-MEM containing 5% FBS, and resuspended in Opti-MEM containing 5% FBS at a density of 3 million cells/ml. pTM1-MXR was constructed by ligating an NcoI-BamHI fragment from a TA cloning vector containing the MXR/BCRP/ABCP gene variants into the vaccinia virus expression plasmid pTM1.

Cytotoxicity Assays.
Cytotoxicity assays were performed using the sulforhodamine method described previously (4) . Cells were exposed to mitoxantrone, topotecan, adriamycin, and SN-38 at various concentrations for 96 h. Each concentration was tested in triplicate, and controls were done in replicates of eight.

	Results

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

 
Disparate Transport of Rhodamine 123 and Mitoxantrone in MXR/BCRP/ABCP-overexpressing Cells.
Rhodamine and mitoxantrone accumulation and efflux assays were performed on nine MXR/BCRP/ABCP-overexpressing sublines and two parental cell lines, MCF-7 human breast cancer cells and S1 human colon cancer cells. The assays were performed in the presence or absence of the MXR/BCRP/ABCP inhibitor FTC. All resistant sublines demonstrated reduced mitoxantrone accumulation, whereas only two (MCF-7 AdVp3000 and S1-M1-80) were found to transport rhodamine 123. Six of the nine sublines studied are shown in Fig. 1A . When mitoxantrone was the substrate, fluorescence after a period of efflux in the absence of FTC (····) is less than after efflux in the presence of FTC (----). In contrast, when similar studies were performed with rhodamine, reduced fluorescence after a period of efflux was observed only in MCF-7 AdVp3000 and S1-M1-80 cells. In these two cell lines, rhodamine efflux was also inhibited by FTC, as shown by the differences in fluorescence between the two histograms (···· versus ----). That the differences in efflux capabilities were not a result of differences in protein levels is shown in the immunoblot in Fig. 1B . High protein levels are found in MCF-7 AdVp3000 and S1-M1-80 cells, both of which have reduced rhodamine accumulation, and also in MCF MX100 and MCF FLV1000, which do not. Somewhat lower levels were found in MCF-7 MX8 and A549 MX10 cells, consistent with the mitoxantrone efflux results.

View larger version (40K): [in this window] [in a new window] [Download PPT slide]   Fig. 1. Characterization of acquired mutations in MXR/BCRP/ABCP-overexpressing cells. A, disparate transport of mitoxantrone and rhodamine 123. Cells were incubated for 30 min with media alone (); incubated with 0.5 µg/ml rhodamine or 20 µM mitoxantrone, washed, and then allowed to incubate for 60 min in media alone (····); or incubated in the presence of 10 µM FTC, with 0.5 µg/ml rhodamine or 20 µM mitoxantrone washed, and then allowed to incubate for 60 min in media containing only 10 µM FTC (----). B, Western blot analysis of MXR/BCRP/ABCP-overexpressing cells. Membrane protein from the six cell lines in A was incubated with the polyclonal MXR/BCRP/ABCP antibody 87405. C, electropherograms for MCF-7 MX100 (R482, top), S1-M1-80 (R482G, middle), and MCF-7 AdVp3000 (R482T, bottom) MXR/BCRP/ABCP forms.

Differential Sensitivity to Chemotherapy Drugs.
To determine whether the mutations identified in the two drug-resistant cell lines could affect the cross-resistance profile, we compared the sensitivity of the mutant sublines with that of MCF-7 MX100 (R482) to various chemotherapy agents. These results are summarized in Fig. 3 . All three cell lines were comparably resistant to mitoxantrone, with relative resistance values differing by only 2- to 4-fold. However, the MCF-7 AdVp3000 cells with the R482T mutation were more resistant to adriamycin than the R482 wild type (P = 0.001), whereas S1-M180 cells with the R482G mutation were also more resistant to adriamycin (P = 0.004) but appeared to be less resistant to topotecan and SN-38. However, this latter difference did not reach statistical significance. Because no difference in topotecan transport could be detected between the three MXR forms in infected-transfected HeLa cells, it is possible that these trends may be attributable to mechanisms other than or related to MXR.

View larger version (32K): [in this window] [in a new window] [Download PPT slide]   Fig. 3. Differential sensitivity of cell lines overexpressing wild-type and mutant MXR/BCRP/ABCP forms. Four-day cytotoxicity assays were performed on the MCF-7 MX100 (R482), MCF-7 AdVp3000 (R482T), and S1-M1-80 (R482G) cells with topotecan, mitoxantrone, adriamycin, and SN-38. Results of the cytotoxicity assay are shown in the top row, with the relative resistance of the cell lines given in the bottom row. Relative resistance values were obtained by dividing the IC50 value of the resistant subline by the IC50 value of the parent cell line and were calculated from the average IC50 obtained from three separate experiments performed in quadruplicate. Using an unpaired Student’s t test, Ps were obtained to evaluate significant differences between cell lines containing the mutation and the wild-type MXR/BCRP/ABCP forms. Only differences with adriamycin were statistically significant.

	Discussion

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

When transmembrane domains for MXR/BCRP/ABCP were identified using the TMpred program, the third transmembrane domain was predicted to span amino acids 483–499 for wild-type MXR/BCRP/ABCP (R482) but was predicted to span amino acids 478–497 for the R482G mutation and 478–499 for the R482T mutation. Thus, the observed differences in drug efflux and resistance may result from a change in the size and/or conformation of the third transmembrane domain. This in turn may result in disruption of the interactions with other transmembrane domains. This view envisions the changes in amino acid 482 as resulting in structural changes beyond its immediate vicinity and considers the transmembrane domain to be adaptable. Alternately, residue 482 may be the site of drug interaction, and mutations at this site may result in altered affinity for different drugs. Although a dimerization partner has not been identified for MXR/BCRP/ABCP, another possibility is that the mutation impacts on the dimerization or oligomerization process.

Mutations in other half-transporters are also known to alter substrate presentation. The human MXR/BCRP/ABCP gene is related to the Drosophila white, brown, and scarlet genes, which encode transporters for eye pigment precursors (1 , 3 , 17) . Mutations in the white gene have been described that significantly impair guanine transport by the White-Brown dimer (I581 del, G589E, and F590G), leaving intact tryptophan transport by the White-Scarlet dimer (6 , 18) . Both G589E and F590G are located near the extracellular surface of transmembrane segment five.

Spontaneous mutations are also known to alter the resistance profile of other drug transporters. Colchicine-selected KB cells were found to overexpress a Pgp that was preferentially resistant to colchicine because of a G185V mutation. Amino acid 185 is predicted to be within the first hydrophobic domain of Pgp and may be at the site of drug binding (11) . Additionally, Loo and Clarke (19) have made multiple substitutions in various transmembrane segments, affecting substrate specificity. Some of these mutations altered the interaction of antagonists with Pgp, affecting drug resistance reversal. A similar situation could be envisioned for the mutations described herein. Studies are currently underway to determine whether these mutations can affect the action of MXR/BCRP/ABCP inhibitors.

The results obtained with the vaccinia virus expression system also suggest that MXR/BCRP/ABCP may function as a homodimer or multimer because expression of the half-transporter alone yields a functional protein. This confirms results obtained with the BCRP cDNA in stable transfectants (3) . Results with the vaccinia virus also imply that the transporter is localized to the cell surface, as reported for drug-selected lines (20 , 21) . Both of these interpretations remain to be substantiated by experimental data.

In summary, we describe two mutations in the MXR/BCRP/ABCP gene acquired during the course of drug selection. Cells with these mutations have different cross-resistance profiles and categorical differences in rhodamine efflux, confirmed in a vaccinia virus transient expression system. Amino acid 482 may be part of the drug-binding site, or, more likely, mutations in this residue may lead to changes in the third transmembrane domain, resulting in structural alterations and consequent changes in substrate specificity.

	FOOTNOTES

 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ To whom requests for reprints should addressed, at Cancer Therapeutics Branch, National Cancer Institute, NIH, Building 10, Room 12N226, 9000 Rockville Pike, Bethesda, MD 20892. Phone: (301) 496-4916; Fax: (301) 402-0172; E-mail: sebates{at}helix.nih.gov

² Internet address: http://www.gene.ucl.ac.uk/users/hester/abc.html.

³ The abbreviations used are: FBS, fetal bovine serum; FTC, fumitremorgin C.

Received 5/ 1/01. Accepted 7/26/01.

	REFERENCES

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

 

1. Miyake K., Mickley L., Litman T., Zhan Z., Robey R., Cristensen B., Brangi M., Greenberger L., Dean M., Fojo T., Bates S. E. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res., 59: 8-13, 1999.[Abstract/Free Full Text]
2. Yang C. H., Schneider E., Kuo M. L., Volk E. L., Rocchi E., Chen Y. C. BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells. Biochem. Pharmacol., 60: 831-837, 2000.[Medline]
3. Doyle L. A., Yang W., Abruzzo L. V., Krogmann T., Gao Y., Rishi A. K., Ross D. D. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. USA, 95: 15665-15670, 1998.[Abstract/Free Full Text]
4. Brangi M., Litman T., Ciotti M., Nishiyama K., Kohlhagen G., Takimoto C., Robey R., Pommier Y., Fojo T., Bates S. E. Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res., 59: 5938-5946, 1999.[Abstract/Free Full Text]
5. Robey R. W., Medina-Perez W. Y., Nishiyama K., Lahusen T., Miyake K., Litman T., Senderowicz A. M., Ross D. D., Bates S. E. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (MXR/BCRP/ABCP1), in flavopiridol-resistant human breast cancer cells. Clin. Cancer Res., 7: 145-152, 2001.[Abstract/Free Full Text]
6. Ewart G. D., Howells A. J. ABC transporters involved in transport of eye pigment precursors in Drosophila melanogaster Ambudkar S. Gottesman M. M. eds. . Methods in Enzymology, Vol. 292: 213-224, Academic Press, Inc. San Diego, CA 1998.[Medline]
7. Berge K. E., Tian H., Graf G. A., Yu L., Grishin N. V., Schultz J., Kwiterovich P., Shan B., Barnes R., Hobbs H. H. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science (Wash. DC), 290: 1771-1775, 2000.[Abstract/Free Full Text]
8. Lee M. H., Lu K., Hazard S., Yu H., Shulenin S., Hidaka H., Kojima H., Allikmets R., Sakuma N., Pegoraro R., Srivastava A. K., Salen G., Dean M., Patel S. B. Identification of a gene, ABCG5, important in the regulation of dietary cholesterol absorption. Nat. Genet., 27: 79-83, 2001.[Medline]
9. Jonker J. W., Smit J. W., Brinkhuis R. F., Maliepaard M., Beijnen J. H., Schellens J. H., Schinkel A. H. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J. Natl. Cancer Inst. (Bethesda), 92: 1651-1656, 2000.[Abstract/Free Full Text]
10. Robey R. W., Honjo Y., van de Laar A., Miyake K., Regis J. T., Litman T., Bates S. E. A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2). Biochim. Biophys. Acta, 1512: 171-182, 2001.[Medline]
11. Choi K., Chen C. J., Kriegler M., Roninson I. B. An altered pattern of cross-resistance in multidrug resistant human cells results from spontaneous mutations in the mdr-1 (P-glycoprotein) gene. Cell, 53: 519-529, 1988.[Medline]
12. Yang C. J., Horton J. K., Cowan K. H., Schneider E. Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations. Cancer Res., 55: 4004-4009, 1995.[Abstract/Free Full Text]
13. Rabindran S. K., He H., Singh M., Brown E., Collins K. I., Annable T., Greenberger L. M. Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. Cancer Res., 58: 5850-5858, 1998.[Abstract/Free Full Text]
14. Litman T., Brangi M., Hudson E., Fetsch P., Abati A., Ross D. D., Miyake K., Resau J. H., Bates S. E. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J. Cell Sci., 113: 2011-2021, 2000.[Abstract]
15. Hrycyna C. A., Ramachandra M., Pastan I., Gottesman M. M. Functional expression of human P-glycoprotein from plasmids using vaccinia virus-bacteriophage T7 RNA polymerase system. Methods Enzymol., 292: 456-473, 1998.[Medline]
16. Hrycyna C. A., Airan L. E., Germann U. A., Ambudkar S. V., Pastan I., Gottesman M. M. Structural flexibility of the linker region of human P-glycoprotein permits ATP hydrolysis and drug transport. Biochemistry, 37: 13660-13673, 1998.[Medline]
17. Allikmets R., Schriml L. M., Hutchinson A., Romano-Spica V., Dean M. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res., 58: 5337-5339, 1998.[Abstract/Free Full Text]
18. Mackenzie S. M., Brooker M. R., Gill T. R., Cox G. B., Howells A. J., Ewart G. D. Mutations in the white gene of Drosophila melanogaster affecting ABC transporters that determine eye colouration. Biochim. Biophys. Acta, 1419: 173-185, 1999.[Medline]
19. Loo T. W., Clarke D. M. Determining the structure and mechanism of the human multidrug resistance P-glycoprotein using cysteine-scanning mutagenesis and thiol-modification techniques. Biochim. Biophys. Acta, 1461: 315-325, 1999.[Medline]
20. Rocchi E., Khodjakov A., Volk E. L., Yang C. H., Litman T., Bates S. E., Schneider E. The product of the ABC half-transporter gene ABCG2 (BCRP/MXR/ABCP) is expressed in the plasma membrane. Biochem. Biophys. Res. Commun., 271: 42-46, 2000.[Medline]
21. Scheffer G. L., Maliepaard M., Pijnenborg A. C. L. M., van Gastelen M. A., de Jong M. C., Schroeijers A. B., van der Kolk D. M., Allen J. D., Ross D. D., van der Valk P., Dalton W. S., Schellens J. H. M., Scheper R. J. Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines. Cancer Res., 60: 2589-2593, 2000.[Abstract/Free Full Text]

This article has been cited by other articles:

				M. Solazzo, O. Fantappie, M. D'Amico, C. Sassoli, A. Tani, G. Cipriani, C. Bogani, L. Formigli, and R. Mazzanti Mitochondrial Expression and Functional Activity of Breast Cancer Resistance Protein in Different Multiple Drug-Resistant Cell Lines Cancer Res., September 15, 2009; 69(18): 7235 - 7242. [Abstract] [Full Text] [PDF]

				M. Huls, F. G. M. Russel, and R. Masereeuw The Role of ATP Binding Cassette Transporters in Tissue Defense and Organ Regeneration J. Pharmacol. Exp. Ther., January 1, 2009; 328(1): 3 - 9. [Abstract] [Full Text] [PDF]

				C.-l. Dai, A. K. Tiwari, C.-P. Wu, X.-d. Su, S.-R. Wang, D.-g. Liu, C. R. Ashby Jr., Y. Huang, R. W. Robey, Y.-j. Liang, et al. Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2 Cancer Res., October 1, 2008; 68(19): 7905 - 7914. [Abstract] [Full Text] [PDF]

				J. Mishra, Q. Zhang, J. L. Rosson, J. Moran, J. M. Dopp, and B. L. Neudeck Lipopolysaccharide Increases Cell Surface P-glycoprotein That Exhibits Diminished Activity in Intestinal Epithelial Cells Drug Metab. Dispos., October 1, 2008; 36(10): 2145 - 2149. [Abstract] [Full Text] [PDF]

				D. K. Hiwase, V. Saunders, D. Hewett, A. Frede, S. Zrim, P. Dang, L. Eadie, L. B. To, J. Melo, S. Kumar, et al. Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications Clin. Cancer Res., June 15, 2008; 14(12): 3881 - 3888. [Abstract] [Full Text] [PDF]

				S. Velamakanni, T. Janvilisri, S. Shahi, and H. W. van Veen A Functional Steroid-Binding Element in an ATP-Binding Cassette Multidrug Transporter Mol. Pharmacol., January 1, 2008; 73(1): 12 - 17. [Abstract] [Full Text] [PDF]

				C.-P. Wu, S. Shukla, A. M. Calcagno, M. D. Hall, M. M. Gottesman, and S. V. Ambudkar Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance linked ABCG2 transporter Mol. Cancer Ther., December 1, 2007; 6(12): 3287 - 3296. [Abstract] [Full Text] [PDF]

				Z. Shi, X.-X. Peng, I.-W. Kim, S. Shukla, Q.-S. Si, R. W. Robey, S. E. Bates, T. Shen, C. R. Ashby Jr., L.-W. Fu, et al. Erlotinib (Tarceva, OSI-774) Antagonizes ATP-Binding Cassette Subfamily B Member 1 and ATP-Binding Cassette Subfamily G Member 2 Mediated Drug Resistance Cancer Res., November 15, 2007; 67(22): 11012 - 11020. [Abstract] [Full Text] [PDF]

				H. Glavinas, E. Kis, A. Pal, R. Kovacs, M. Jani, E. Vagi, E. Molnar, S. Bansaghi, Z. Kele, T. Janaky, et al. ABCG2 (Breast Cancer Resistance Protein/Mitoxantrone Resistance-Associated Protein) ATPase Assay: A Useful Tool to Detect Drug-Transporter Interactions Drug Metab. Dispos., September 1, 2007; 35(9): 1533 - 1542. [Abstract] [Full Text] [PDF]

				A. Pal, D. Mehn, E. Molnar, S. Gedey, P. Meszaros, T. Nagy, H. Glavinas, T. Janaky, O. von Richter, G. Bathori, et al. Cholesterol Potentiates ABCG2 Activity in a Heterologous Expression System: Improved in Vitro Model to Study Function of Human ABCG2 J. Pharmacol. Exp. Ther., June 1, 2007; 321(3): 1085 - 1094. [Abstract] [Full Text] [PDF]

				C. Q. Xia, N. Liu, G. T. Miwa, and L.-S. Gan Interactions of Cyclosporin A with Breast Cancer Resistance Protein Drug Metab. Dispos., April 1, 2007; 35(4): 576 - 582. [Abstract] [Full Text] [PDF]

				S. S. Lee, H.-E. Jeong, J.-M. Yi, H.-J. Jung, J.-E. Jang, E.-Y. Kim, S.-J. Lee, and J.-G. Shin Identification and Functional Assessment of BCRP Polymorphisms in a Korean Population Drug Metab. Dispos., April 1, 2007; 35(4): 623 - 632. [Abstract] [Full Text] [PDF]

				P. Breedveld, D. Pluim, G. Cipriani, F. Dahlhaus, M. A. J. van Eijndhoven, C. J. F. de Wolf, A. Kuil, J. H. Beijnen, G. L. Scheffer, G. Jansen, et al. The Effect of Low pH on Breast Cancer Resistance Protein (ABCG2)-Mediated Transport of Methotrexate, 7-Hydroxymethotrexate, Methotrexate Diglutamate, Folic Acid, Mitoxantrone, Topotecan, and Resveratrol in In Vitro Drug Transport Models Mol. Pharmacol., January 1, 2007; 71(1): 240 - 249. [Abstract] [Full Text] [PDF]

				J. G. Turner, J. L. Gump, C. Zhang, J. M. Cook, D. Marchion, L. Hazlehurst, P. Munster, M. J. Schell, W. S. Dalton, and D. M. Sullivan ABCG2 expression, function, and promoter methylation in human multiple myeloma Blood, December 1, 2006; 108(12): 3881 - 3889. [Abstract] [Full Text] [PDF]

				B. Sarkadi, L. Homolya, G. Szakacs, and A. Varadi Human Multidrug Resistance ABCB and ABCG Transporters: Participation in a Chemoimmunity Defense System. Physiol Rev, October 1, 2006; 86(4): 1179 - 1236. [Abstract] [Full Text] [PDF]

				J. A. Seamon, C. A. Rugg, S. Emanuel, A. M. Calcagno, S. V. Ambudkar, S. A. Middleton, J. Butler, V. Borowski, and L. M. Greenberger Role of the ABCG2 drug transporter in the resistance and oral bioavailability of a potent cyclin-dependent kinase/Aurora kinase inhibitor. Mol. Cancer Ther., October 1, 2006; 5(10): 2459 - 2467. [Abstract] [Full Text] [PDF]

				W. Chearwae, S. Shukla, P. Limtrakul, and S. V. Ambudkar Modulation of the function of the multidrug resistance-linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin. Mol. Cancer Ther., August 1, 2006; 5(8): 1995 - 2006. [Abstract] [Full Text] [PDF]

				S. Choudhuri and C. D. Klaassen Structure, Function, Expression, Genomic Organization, and Single Nucleotide Polymorphisms of Human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) Efflux Transporters International Journal of Toxicology, July 1, 2006; 25(4): 231 - 259. [Abstract] [Full Text] [PDF]

				H. E. M. zu Schwabedissen, M. Grube, A. Dreisbach, G. Jedlitschky, K. Meissner, K. Linnemann, C. Fusch, C. A. Ritter, U. Volker, and H. K. Kroemer EPIDERMAL GROWTH FACTOR-MEDIATED ACTIVATION OF THE MAP KINASE CASCADE RESULTS IN ALTERED EXPRESSION AND FUNCTION OF ABCG2 (BCRP) Drug Metab. Dispos., April 1, 2006; 34(4): 524 - 533. [Abstract] [Full Text] [PDF]

				K. Meissner, B. Heydrich, G. Jedlitschky, H. Meyer zu Schwabedissen, I. Mosyagin, P. Dazert, L. Eckel, S. Vogelgesang, R. W. Warzok, M. Bohm, et al. The ATP-binding Cassette Transporter ABCG2 (BCRP), a Marker for Side Population Stem Cells, Is Expressed in Human Heart J. Histochem. Cytochem., February 1, 2006; 54(2): 215 - 221. [Abstract] [Full Text] [PDF]

				Z. Benderra, A. M. Faussat, L. Sayada, J.-Y. Perrot, R. Tang, D. Chaoui, H. Morjani, C. Marzac, J.-P. Marie, and O. Legrand MRP3, BCRP, and P-Glycoprotein Activities are Prognostic Factors in Adult Acute Myeloid Leukemia Clin. Cancer Res., November 1, 2005; 11(21): 7764 - 7772. [Abstract] [Full Text] [PDF]

				A. Shafran, I. Ifergan, E. Bram, G. Jansen, I. Kathmann, G. J. Peters, R. W. Robey, S. E. Bates, and Y. G. Assaraf ABCG2 Harboring the Gly482 Mutation Confers High-Level Resistance to Various Hydrophilic Antifolates Cancer Res., September 15, 2005; 65(18): 8414 - 8422. [Abstract] [Full Text] [PDF]

				C.-H. Yang, C.-J. Huang, C.-S. Yang, Y.-C. Chu, A.-L. Cheng, J. Whang-Peng, and P.-C. Yang Gefitinib Reverses Chemotherapy Resistance in Gefitinib-Insensitive Multidrug Resistant Cancer Cells Expressing ATP-Binding Cassette Family Protein Cancer Res., August 1, 2005; 65(15): 6943 - 6949. [Abstract] [Full Text] [PDF]

				Y. Liu, H. Peng, and J.-T. Zhang Expression Profiling of ABC Transporters in a Drug-Resistant Breast Cancer Cell Line Using AmpArray Mol. Pharmacol., August 1, 2005; 68(2): 430 - 438. [Abstract] [Full Text] [PDF]

				C. Q. Xia, N. Liu, D. Yang, G. Miwa, and L.-S. Gan EXPRESSION, LOCALIZATION, AND FUNCTIONAL CHARACTERISTICS OF BREAST CANCER RESISTANCE PROTEIN IN CACO-2 CELLS Drug Metab. Dispos., May 1, 2005; 33(5): 637 - 643. [Abstract] [Full Text] [PDF]

				Y. Adachi, H. Suzuki, A. H. Schinkel, and Y. Sugiyama Role of Breast Cancer Resistance Protein (Bcrp1/Abcg2) in the Extrusion of Glucuronide and Sulfate Conjugates from Enterocytes to Intestinal Lumen Mol. Pharmacol., March 1, 2005; 67(3): 923 - 928. [Abstract] [Full Text] [PDF]

				K. F. K. Ejendal and C. A. Hrycyna Differential Sensitivities of the Human ATP-Binding Cassette Transporters ABCG2 and P-Glycoprotein to Cyclosporin A Mol. Pharmacol., March 1, 2005; 67(3): 902 - 911. [Abstract] [Full Text] [PDF]

				Y. Nakamura, M. Oka, H. Soda, K. Shiozawa, M. Yoshikawa, A. Itoh, Y. Ikegami, J. Tsurutani, K. Nakatomi, T. Kitazaki, et al. Gefitinib ("Iressa", ZD1839), an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses Breast Cancer Resistance Protein/ABCG2-Mediated Drug Resistance Cancer Res., February 15, 2005; 65(4): 1541 - 1546. [Abstract] [Full Text] [PDF]

				D. Kobayashi, I. Ieiri, T. Hirota, H. Takane, S. Maegawa, J. Kigawa, H. Suzuki, E. Nanba, M. Oshimura, N. Terakawa, et al. FUNCTIONAL ASSESSMENT OF ABCG2 (BCRP) GENE POLYMORPHISMS TO PROTEIN EXPRESSION IN HUMAN PLACENTA Drug Metab. Dispos., January 1, 2005; 33(1): 94 - 101. [Abstract] [Full Text] [PDF]

				P. Pavek, G. Merino, E. Wagenaar, E. Bolscher, M. Novotna, J. W. Jonker, and A. H. Schinkel Human Breast Cancer Resistance Protein: Interactions with Steroid Drugs, Hormones, the Dietary Carcinogen 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and Transport of Cimetidine J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 144 - 152. [Abstract] [Full Text] [PDF]

				P.L. R. Ee, X. He, D. D. Ross, and W. T. Beck Modulation of breast cancer resistance protein (BCRP/ABCG2) gene expression using RNA interference Mol. Cancer Ther., December 1, 2004; 3(12): 1577 - 1584. [Abstract] [Full Text] [PDF]

				H. Burger, H. van Tol, A. W. M. Boersma, M. Brok, E. A. C. Wiemer, G. Stoter, and K. Nooter Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump Blood, November 1, 2004; 104(9): 2940 - 2942. [Abstract] [Full Text] [PDF]

				S. E. Bates, W. Y. Medina-Perez, G. Kohlhagen, S. Antony, T. Nadjem, R. W. Robey, and Y. Pommier ABCG2 Mediates Differential Resistance to SN-38 (7-Ethyl-10-hydroxycamptothecin) and Homocamptothecins J. Pharmacol. Exp. Ther., August 1, 2004; 310(2): 836 - 842. [Abstract] [Full Text] [PDF]

				A. Gupta, Y. Zhang, J. D. Unadkat, and Q. Mao HIV Protease Inhibitors Are Inhibitors but Not Substrates of the Human Breast Cancer Resistance Protein (BCRP/ABCG2) J. Pharmacol. Exp. Ther., July 1, 2004; 310(1): 334 - 341. [Abstract] [Full Text] [PDF]

				H. Minderman, K. L. O'Loughlin, L. Pendyala, and M. R. Baer VX-710 (Biricodar) Increases Drug Retention and Enhances Chemosensitivity in Resistant Cells Overexpressing P-Glycoprotein, Multidrug Resistance Protein, and Breast Cancer Resistance Protein Clin. Cancer Res., March 1, 2004; 10(5): 1826 - 1834. [Abstract] [Full Text] [PDF]

				R. W. Robey, K. Steadman, O. Polgar, K. Morisaki, M. Blayney, P. Mistry, and S. E. Bates Pheophorbide a Is a Specific Probe for ABCG2 Function and Inhibition Cancer Res., February 15, 2004; 64(4): 1242 - 1246. [Abstract] [Full Text] [PDF]

				C G Dietrich, A Geier, and R P J Oude Elferink ABC of oral bioavailability: transporters as gatekeepers in the gut Gut, December 1, 2003; 52(12): 1788 - 1795. [Full Text] [PDF]

				T. Nakanishi, L. A. Doyle, B. Hassel, Y. Wei, K. S. Bauer, S. Wu, D. W. Pumplin, H.-B. Fang, and D. D. Ross Functional Characterization of Human Breast Cancer Resistance Protein (BCRP, ABCG2) Expressed in the Oocytes of Xenopus laevis Mol. Pharmacol., December 1, 2003; 64(6): 1452 - 1462. [Abstract] [Full Text] [PDF]

				S. L. A. Plasschaert, D. M. van der Kolk, E. S. J. M. de Bont, W. A. Kamps, K. Morisaki, S. E. Bates, G. L. Scheffer, R. J. Scheper, E. Vellenga, and E. G. E. de Vries The Role of Breast Cancer Resistance Protein in Acute Lymphoblastic Leukemia Clin. Cancer Res., November 1, 2003; 9(14): 5171 - 5177. [Abstract] [Full Text] [PDF]

				T. Brooks, H. Minderman, K. L. O'Loughlin, P. Pera, I. Ojima, M. R. Baer, and R. J. Bernacki Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein Mol. Cancer Ther., November 1, 2003; 2(11): 1195 - 1205. [Abstract] [Full Text] [PDF]

				E. L. Volk and E. Schneider Wild-Type Breast Cancer Resistance Protein (BCRP/ABCG2) is a Methotrexate Polyglutamate Transporter Cancer Res., September 1, 2003; 63(17): 5538 - 5543. [Abstract] [Full Text] [PDF]

				Y. Imai, S. Asada, S. Tsukahara, E. Ishikawa, T. Tsuruo, and Y. Sugimoto Breast Cancer Resistance Protein Exports Sulfated Estrogens but Not Free Estrogens Mol. Pharmacol., September 1, 2003; 64(3): 610 - 618. [Abstract] [Full Text] [PDF]

				M. Wierdl, A. Wall, C. L. Morton, J. Sampath, M. K. Danks, J. D. Schuetz, and P. M. Potter Carboxylesterase-Mediated Sensitization of Human Tumor Cells to CPT-11 Cannot Override ABCG2-Mediated Drug Resistance Mol. Pharmacol., August 1, 2003; 64(2): 279 - 288. [Abstract] [Full Text] [PDF]

				T. Nakanishi, J. E. Karp, M. Tan, L. A. Doyle, T. Peters, W. Yang, D. Wei, and D. D. Ross Quantitative Analysis of Breast Cancer Resistance Protein and Cellular Resistance to Flavopiridol in Acute Leukemia Patients Clin. Cancer Res., August 1, 2003; 9(9): 3320 - 3328. [Abstract] [Full Text] [PDF]

				Z.-S. Chen, R. W. Robey, M. G. Belinsky, I. Shchaveleva, X.-Q. Ren, Y. Sugimoto, D. D. Ross, S. E. Bates, and G. D. Kruh Transport of Methotrexate, Methotrexate Polyglutamates, and 17{beta}-Estradiol 17-({beta}-D-glucuronide) by ABCG2: Effects of Acquired Mutations at R482 on Methotrexate Transport Cancer Res., July 15, 2003; 63(14): 4048 - 4054. [Abstract] [Full Text] [PDF]

				A. C. Lockhart, R. G. Tirona, and R. B. Kim Pharmacogenetics of ATP-binding Cassette Transporters in Cancer and Chemotherapy Mol. Cancer Ther., July 1, 2003; 2(7): 685 - 698. [Abstract] [Full Text] [PDF]

				R. Rajendra, M. K. Gounder, A. Saleem, J. H. M. Schellens, D. D. Ross, S. E. Bates, P. Sinko, and E. H. Rubin Differential Effects of the Breast Cancer Resistance Protein on the Cellular Accumulation and Cytotoxicity of 9-Aminocamptothecin and 9-Nitrocamptothecin Cancer Res., June 15, 2003; 63(12): 3228 - 3233. [Abstract] [Full Text] [PDF]

				M. Suzuki, H. Suzuki, Y. Sugimoto, and Y. Sugiyama ABCG2 Transports Sulfated Conjugates of Steroids and Xenobiotics J. Biol. Chem., June 13, 2003; 278(25): 22644 - 22649. [Abstract] [Full Text] [PDF]

				J. D. Allen, S. C. van Dort, M. Buitelaar, O. van Tellingen, and A. H. Schinkel Mouse Breast Cancer Resistance Protein (Bcrp1/Abcg2) Mediates Etoposide Resistance and Transport, but Etoposide Oral Availability Is Limited Primarily by P-glycoprotein Cancer Res., March 15, 2003; 63(6): 1339 - 1344. [Abstract] [Full Text] [PDF]

				X. Wang, T. Furukawa, T. Nitanda, M. Okamoto, Y. Sugimoto, S.-I. Akiyama, and M. Baba Breast Cancer Resistance Protein (BCRP/ABCG2) Induces Cellular Resistance to HIV-1 Nucleoside Reverse Transcriptase Inhibitors Mol. Pharmacol., January 1, 2003; 63(1): 65 - 72. [Abstract] [Full Text] [PDF]

				B. L. Abbott, A.-M. Colapietro, Y. Barnes, F. Marini, M. Andreeff, and B. P. Sorrentino Low levels of ABCG2 expression in adult AML blast samples Blood, December 15, 2002; 100(13): 4594 - 4601. [Abstract] [Full Text] [PDF]

				C. Ozvegy, A. Varadi, and B. Sarkadi Characterization of Drug Transport, ATP Hydrolysis, and Nucleotide Trapping by the Human ABCG2 Multidrug Transporter. MODULATION OF SUBSTRATE SPECIFICITY BY A POINT MUTATION J. Biol. Chem., December 6, 2002; 277(50): 47980 - 47990. [Abstract] [Full Text] [PDF]

				E. L. Volk, K. M. Farley, Y. Wu, F. Li, R. W. Robey, and E. Schneider Overexpression of Wild-Type Breast Cancer Resistance Protein Mediates Methotrexate Resistance Cancer Res., September 1, 2002; 62(17): 5035 - 5040. [Abstract] [Full Text] [PDF]

				J. D. Allen, S. C. Jackson, and A. H. Schinkel A Mutation Hot Spot in the Bcrp1 (Abcg2) Multidrug Transporter in Mouse Cell Lines Selected for Doxorubicin Resistance Cancer Res., April 1, 2002; 62(8): 2294 - 2299. [Abstract] [Full Text] [PDF]

				J. D. Allen and A. H. Schinkel Multidrug Resistance and Pharmacological Protection Mediated by the Breast Cancer Resistance Protein (BCRP/ABCG2) Mol. Cancer Ther., April 1, 2002; 1(6): 427 - 434. [Full Text] [PDF]

				I. F. Faneyte, P. M. P. Kristel, M. Maliepaard, G. L. Scheffer, R. J. Scheper, J. H. M. Schellens, and M. J. van de Vijver Expression of the Breast Cancer Resistance Protein in Breast Cancer Clin. Cancer Res., April 1, 2002; 8(4): 1068 - 1074. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Honjo, Y. Articles by Bates, S. E. Search for Related Content PubMed PubMed Citation Articles by Honjo, Y. Articles by Bates, S. E.